DBV Technologies S.A.
DBVT$3.77B
Mid CapNASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaCHATILLON
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
DBVT News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
No drugs found in this phase.
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply